CTMX Q4 2023 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$846M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$27M+32.2% YoY

Gross Profit

$27M100.0% margin

Operating Income

-$606,000-2.3% margin

Net Income

$837,0003.1% margin

EPS (Diluted)

$0.01

QoQ Revenue Growth

+0.8%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$202M

Total Liabilities

$249M

Stockholders' Equity

-$47M

Cash & Equivalents

$17M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$27M	$20M	+32.2%
Gross Profit	$27M	$20M	+32.2%
Operating Income	-$606,000	-$10M	+93.6%
Net Income	$837,000	-$9M	+109.5%